References
- Katzung, B. G. Basic and Clinical Pharmacology, 12th ed.; The McGraw-Hill Companies: New York, NY, 2012.
- Tripathi, K. D. Essential of Medical Pharmacology, 7th ed.; Jaypee Brother’s Medical Publishers: New Delhi, 2013.
- The Merck Index, 15th ed.; RSC Publishing: London, 2013.
- Indian Pharmacopoeia, 8th ed.; Indian Pharmacopoeia Commission. Government of India, Ministry of Health and Family Welfare: Ghaziabad, 2018.
- López-Rodríguez, R.; McManus, J. A.; Murphy, N. S.; Ott, M. A.; Burns, M. J. Pathways for N-Nitroso Compound Formation: Secondary Amines and Beyond. Org. Process Res. Dev. 2020, 24, 1558–1585. DOI:10.1021/ACS.OPRD.0C00323/ASSET/IMAGES/MEDIUM/OP0C00323_0094.GIF.
- Control of Nitrosamine Impurities in Human Drugs Guidance for Industry; 2021.
- European Medicines Agency, Committee for Human Medicinal Products ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk, 2015.
- U.S. Food and Drug Administration (FDA). Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product, 2020.
- Lim, H. H.; Oh, Y. S.; Shin, H. S. Determination of N-Nitrosodimethylamine and N-Nitrosomethylethylamine in Drug Substances and Products of Sartans, Metformin and Ranitidine by Precipitation and Solid Phase Extraction and Gas Chromatography–Tandem Mass Spectrometry. J. Pharm. Biomed. Anal. 2020, 189, 113460. DOI:10.1016/J.JPBA.2020.113460.
- Chidella, K. S.; Dasari, V. B.; Anireddy, J.; Chidella, K. S.; Dasari, V. B.; Anireddy, J. Ultra-Sensitive LC-MS/MS Method for the Trace Level Quantification of Six Potential Genotoxic Nitrosamine Impurities in Telmisartan. AJAC 2021, 12, 227–240. DOI:10.4236/ajac.2021.126014.
- Masada, S.; Tsuji, G.; Arai, R.; Uchiyama, N.; Demizu, Y.; Tsutsumi, T.; Abe, Y.; Akiyama, H.; Hakamatsuka, T.; Izutsu, K.; et al. Rapid and Efficient High-Performance Liquid Chromatography Analysis of N-Nitrosodimethylamine Impurity in Valsartan Drug Substance and Its Products. Sci. Rep. 2019, 91, 1–6. DOI:10.1038/s41598-019-48344-5.
- U.S. Food and Drug Administration (FDA). Liquid Chromatography-High Resolution MasSpectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product, 2019.
- Shrivas, N.; Mishra, S. K. Analytical Method Development and Validation for Limit of N-Nitrosodimethylamine by LC-MS/MS of Empagliflozin, Linagliptin and Metformin HCL Extended-Release Tablets. JMPAS 2021, 10, 3534–3537. DOI:10.22270/jmpas.V10I5.1695.
- Q2(R1) Validation of Analytical Procedures: Text and Methodology Guidance for Industry; FDA, 2021.
- Solanki, R. V.; Patel, R. B.; Patel, R. K.; Patel, B. M. The Development and Validation of Fast and Robust Stability Indicating RP-HPLC Method for Simultaneous Estimation of Azilsartan Medoxomil and Cilnidipine in Pharmaceutical Dosage Form. IJPI 2022, 12, 293–298. DOI:10.5530/ijpi.2022.3.51.
- Solanki, R. V.; Patel, R. B.; Patel, R. K.; Sheth, R. A. Development and Validation of Fast and Robust Stability Indicating RP-HPLC Method for Simultaneous Estimation of Tolperisone Hydrochloride and Etoricoxib in Pharmaceutical Dosage Form. IJPI 2022, 12, 56–61. DOI:10.5530/ijpi.2022.1.10.
- Patel, R.; Dube, A.; Solanki, R.; Khunt, D.; Parikh, S.; Junnuthula, V.; Dyawanapelly, S. Structural Elucidation of Alkali Degradation Impurities of Favipiravir from the Oral Suspension: UPLC-TQ-ESI-MS/MS and NMR. Molecules 2022, 27, 5606. DOI:10.3390/molecules27175606.